Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis

A 60-year-old woman was diagnosed with cT4N3M1c stage IVB lung adenocarcinoma with epidermal growth factor receptor mutation of exon19 deletion. After one month of treatment with osimertinib, a cough and diffuse ground glass opacities were observed in the bilateral lung field. Based on the clinical...

Full description

Bibliographic Details
Published in:	Respiratory Medicine Case Reports
Main Authors:	Taisuke Ito, Kazuo Tsuchiya, Rie Mori, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Subjects:	Osimertinib Osimertinib-induced pneumonitis Re-administration Desensitization EGFR-TKI
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213007124000522

Similar Items

Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
by: Clayton P. Smith, MD, et al.
Published: (2023-03-01)

Involvement of naïve T cells in the pathogenesis of osimertinib-induced pneumonitis
by: Hiroyuki Ando, et al.
Published: (2025-03-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
by: Rui Han, et al.
Published: (2020-06-01)

Drug-induced subacute cutaneous lupus erythematosus involving osimertinib
by: Christian L. Bailey-Burke, AB, et al.
Published: (2024-11-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)

Airway stenosis secondary to mediastinal lymph node metastasis of lung adenocarcinoma treated with AERO stent and osimertinib: A case report
by: Yuki Takigawa, et al.
Published: (2024-05-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
by: Toru Imai, et al.
Published: (2024-03-01)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
by: Leou Ismael Banla, MD, PhD, et al.
Published: (2023-10-01)

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01)

Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report
by: Sareen T. Ali, et al.
Published: (2024-07-01)

NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature
by: Alberto P. Romagnolo, et al.
Published: (2023-06-01)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01)

Case Report: Osimertinib-induced acute interstitial lung disease
by: Zhiwu Lin, et al.
Published: (2025-06-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01)

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
by: Bradley Steiner, et al.
Published: (2025-06-01)

Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature
by: Blerina Resuli, et al.
Published: (2025-05-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01)

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
by: Atul Tiwari, et al.

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
by: Marcin Skrzypski, et al.
Published: (2017-09-01)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
by: Hanping Wang, et al.
Published: (2020-03-01)

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
by: Patricia L. Theard, et al.
Published: (2024-03-01)

Clinical study of aumolertinib versus osimertinib in the treatment of EGFR-mutated advanced non-small cell lung cancer
by: Sheng-Xi Yang, et al.
Published: (2025-10-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
by: Sunny Y. Lai, MD, et al.
Published: (2024-04-01)

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression
by: Nalini Devi Verusingam, et al.
Published: (2025-09-01)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
by: Yuan‐Ling Cheng, et al.
Published: (2022-08-01)

HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells
by: Hanbing Lyu, et al.
Published: (2025-06-01)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
by: Xinyu von Buttlar, MD, MS, et al.
Published: (2021-06-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
by: Hsu-Yuan Chen, et al.
Published: (2024-10-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
by: Yusuke Hamakawa, et al.
Published: (2023-09-01)

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report
by: Hailey M. Hirata, PharmD, et al.
Published: (2025-04-01)

Osimertinib‐induced BRAF mutation in a single metastatic lesion among multiple pulmonary lesions in a case of lung cancer with EGFR exon 19 deletion
by: Hiroyuki Miura, et al.
Published: (2024-08-01)

Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment
by: J.W. Tijmen van der Wel, MD, et al.
Published: (2025-09-01)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
by: Takahiro Uchida, et al.
Published: (2019-04-01)

Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review
by: Wenting Lu, et al.
Published: (2025-03-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
by: Richard E. Kast, et al.
Published: (2021-05-01)